



an Open Access Journal by MDPI

Cancer Immunotherapy: Molecular Mechanisms and Novel Potential Targets

Guest Editors:

Dr. Francesca Romana Mariotti

Tumor Immunology Unit, IRCCS Bambino Gesù Children's Hospital, 00146 Rome, Italy

Dr. Martina Molgora

Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO 63110, USA

Dr. Linda Quatrini

Tumor Immunology Unit, IRCCS Bambino Gesù Children's Hospital, 00146 Rome, Italy

Deadline for manuscript submissions:

closed (30 June 2023)

Message from the Guest Editors

Dear Colleagues,

In recent decades scientists have made significant progress in deciphering the molecular mechanisms involved in cancer immune surveillance and immune escape, helping to develop novel and more effective immunotherapies, including oncolytic virus therapies, cytokines therapies, cancer vaccines, immune checkpoint inhibitors and adoptive cell transfer. This Special Issue encourages authors to present recent progress in the following areas:

- Discerning undefined interactions between immune cells and tumor cells or stroma (cell–cell inhibition, ECM, CAFs, distal stroma and metastases)
- Discovering novel putative targets (i.e., neo-antigens, cytokines and receptors) to develop more specific and successful therapies,
- Eliciting the different genetic (i.e., HLA, non-coding RNA) and environmental (i.e., microbiome, virus infections, co-morbidity) contexts that may affect the outcome of cancer immunotherapies.

In this Special Issue, original research articles and reviews are welcome.

Dr. Biancamaria Ricci

Dr. Francesca Romana Mariotti

Dr. Martina Molgora

Guest Editors



mdpi.com/si/158386

Special Issue



an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPLus / SciFinder*, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](https://twitter.com/Biomed_MDPI)